Overview

A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacokinetics of AFQ056 in subjects with mild, moderate, severe hepatic impairment compared with healthy control subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals